Loading...
•
Sep 30, 2021
Generation Bio Q3 2021 Earnings Report
Generation Bio's financial position and operational performance were detailed for Q3 2021.
Key Takeaways
Generation Bio reported a net loss of $31.9 million for Q3 2021, with cash, cash equivalents, and marketable securities totaling $398.4 million as of September 30, 2021. The company highlighted preclinical data demonstrating broad delivery of ceDNA and mRNA to photoreceptors using ctLNP.
Cash, cash equivalents and marketable securities were $398.4 million as of September 30, 2021.
Research and development expenses were $22.0 million for the quarter ended September 30, 2021.
General and administrative expenses were $9.7 million for the quarter ended September 30, 2021.
Net loss was $31.9 million, or $0.56 basic and diluted net loss per share, for the quarter ended September 30, 2021.
Generation Bio
Generation Bio
Forward Guidance
This press release contains forward-looking statements regarding Generation Bio's future expectations, plans, and prospects, including statements about strategic plans, technology platform, research and clinical development plans, the timing of IND submissions and preclinical data, manufacturing plans, and expectations regarding a new facility.